Early prostate cancer antigen-2

Jump to: navigation, search

WikiDoc Resources for Early prostate cancer antigen-2

Articles

Most recent articles on Early prostate cancer antigen-2

Most cited articles on Early prostate cancer antigen-2

Review articles on Early prostate cancer antigen-2

Articles on Early prostate cancer antigen-2 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Early prostate cancer antigen-2

Images of Early prostate cancer antigen-2

Photos of Early prostate cancer antigen-2

Podcasts & MP3s on Early prostate cancer antigen-2

Videos on Early prostate cancer antigen-2

Evidence Based Medicine

Cochrane Collaboration on Early prostate cancer antigen-2

Bandolier on Early prostate cancer antigen-2

TRIP on Early prostate cancer antigen-2

Clinical Trials

Ongoing Trials on Early prostate cancer antigen-2 at Clinical Trials.gov

Trial results on Early prostate cancer antigen-2

Clinical Trials on Early prostate cancer antigen-2 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Early prostate cancer antigen-2

NICE Guidance on Early prostate cancer antigen-2

NHS PRODIGY Guidance

FDA on Early prostate cancer antigen-2

CDC on Early prostate cancer antigen-2

Books

Books on Early prostate cancer antigen-2

News

Early prostate cancer antigen-2 in the news

Be alerted to news on Early prostate cancer antigen-2

News trends on Early prostate cancer antigen-2

Commentary

Blogs on Early prostate cancer antigen-2

Definitions

Definitions of Early prostate cancer antigen-2

Patient Resources / Community

Patient resources on Early prostate cancer antigen-2

Discussion groups on Early prostate cancer antigen-2

Patient Handouts on Early prostate cancer antigen-2

Directions to Hospitals Treating Early prostate cancer antigen-2

Risk calculators and risk factors for Early prostate cancer antigen-2

Healthcare Provider Resources

Symptoms of Early prostate cancer antigen-2

Causes & Risk Factors for Early prostate cancer antigen-2

Diagnostic studies for Early prostate cancer antigen-2

Treatment of Early prostate cancer antigen-2

Continuing Medical Education (CME)

CME Programs on Early prostate cancer antigen-2

International

Early prostate cancer antigen-2 en Espanol

Early prostate cancer antigen-2 en Francais

Business

Early prostate cancer antigen-2 in the Marketplace

Patents on Early prostate cancer antigen-2

Experimental / Informatics

List of terms related to Early prostate cancer antigen-2


Overview

Early prostate cancer antigen-2 (EPCA-2) is a protein of which blood levels are elevated in prostate cancer. It appears to provide more accuracy in identifying early prostate cancer than the standard prostate cancer marker, PSA.


EPCA-2 versus PSA

The steady decrease in prostate cancer mortality is indirect evidence that the early detection using serum PSA and rectal examination saves lives. However using serum PSA in screening for prostate cancer remains controversial, because of its low specificity.

Leman and colleagues describe, in the April 2007 issue of Urology, the performance characteristic of EPCA-2, a novel nuclear protein marker for prostate cancer cells.

A study was initiated which suggested that the EPCA-2 protein serum assay exhibits favorable performance characteristics which are potentially superior to serum PSA. However more studies are necessary to see if this test will retain its sensitivity when used in a screening population.

References

  • Leman E, Cannon G, Sokoll L. EPCA-2: A Highly Specific Serum Marker for Prostate Cancer. Proceedings from the 2006 annual meeting of the American Urological Association. Abstract #852.
  • Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, Partin AW, Getzenberg RH. Urology. 69(4):714-20, April 2007


External links



Linked-in.jpg